多瑞医药
(301075)
| 流通市值:23.17亿 | | | 总市值:32.74亿 |
| 流通股本:5660.00万 | | | 总股本:8000.00万 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 149,010,342.42 | 95,655,393.08 | 32,431,205.53 | 154,176,460.28 |
| 营业总成本 | 204,957,790.84 | 137,708,660.18 | 54,224,700.54 | 274,302,230.06 |
| 其他经营收益 | | | | |
| 营业利润 | -652,775.07 | 4,713,818.49 | -18,842,206.09 | -128,374,071.67 |
| 利润总额 | 1,870,603.4 | 6,247,926.59 | -18,951,964.26 | -131,357,431.7 |
| 净利润 | -1,205,916.61 | 3,240,666.51 | -19,014,237.05 | -132,401,390.23 |
| 每股收益 | | | | |
| 其他综合收益 | - | 200,000 | - | - |
| 综合收益总额 | -1,205,916.61 | 3,440,666.51 | -19,014,237.05 | -132,401,390.23 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 527,565,603.74 | 322,042,231.19 | 329,537,715.22 | 329,063,783.83 |
| 非流动资产: | | | | |
| 非流动资产合计 | 934,695,604.8 | 988,127,476.98 | 998,127,031.99 | 954,150,274.46 |
| 资产总计 | 1,462,261,208.54 | 1,310,169,708.17 | 1,327,664,747.21 | 1,283,214,058.29 |
| 流动负债: | | | | |
| 流动负债合计 | 646,487,892.13 | 487,167,681.81 | 451,118,651 | 442,136,519.06 |
| 非流动负债: | | | | |
| 非流动负债合计 | 121,074,309.43 | 123,079,139.36 | 215,532,309.84 | 217,537,139.78 |
| 负债合计 | 767,562,201.56 | 610,246,821.17 | 666,650,960.84 | 659,673,658.84 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 656,596,950.36 | 659,565,510.15 | 617,031,129.65 | 574,511,474.73 |
| 股东权益合计 | 694,699,006.98 | 699,922,887 | 661,013,786.37 | 623,540,399.45 |
| 负债和股东权益合计 | 1,462,261,208.54 | 1,310,169,708.17 | 1,327,664,747.21 | 1,283,214,058.29 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 187,540,020.53 | 127,257,713.05 | 43,606,259.08 | 197,483,273.31 |
| 经营活动现金流出小计 | 251,634,978.55 | 171,691,667.14 | 80,258,766.48 | 243,315,701.9 |
| 经营活动产生的现金流量净额 | -64,094,958.02 | -44,433,954.09 | -36,652,507.4 | -45,832,428.59 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 197,806,505.29 | 98,475,965.6 | 25,553,298.07 | 1,187,736,685.45 |
| 投资活动现金流出小计 | 240,154,697.7 | 68,896,424.79 | 47,696,360.19 | 1,015,151,895.49 |
| 投资活动产生的现金流量净额 | -42,348,192.41 | 29,579,540.81 | -22,143,062.12 | 172,584,789.96 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 265,544,239.45 | 76,403,810.32 | 56,442,970.07 | 127,880,000 |
| 筹资活动现金流出小计 | 91,495,717.35 | 81,904,512.7 | 17,481,267.23 | 279,473,190.49 |
| 筹资活动产生的现金流量净额 | 174,048,522.1 | -5,500,702.38 | 38,961,702.84 | -151,593,190.49 |
| 汇率变动对现金及现金等价物的影响 | - | - | - | -1,462.29 |
| 现金及现金等价物净增加额 | 67,605,371.67 | -20,355,115.66 | -19,833,866.68 | -24,842,291.41 |
| 期末现金及现金等价物余额 | 152,881,402.17 | 64,920,914.84 | 65,444,163.82 | 85,276,030.5 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -20,355,115.66 | - | -24,842,291.41 |